Geneos Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Geneos Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23	Closed	-$1K	–	3111
2021 Q1	$1K	Buy	+23	New	+$1.8K	﹤0.01%	3065
2019 Q1	–	Sell	-142	Closed	-$27K	–	2464
2018 Q4	$27K	Buy	142 +2	+1%	+$488	﹤0.01%	1377
2018 Q3	$45K	Hold	140	–	–	﹤0.01%	1219
2018 Q2	$43K	Hold	140	–	–	﹤0.01%	1119
2018 Q1	$34K	Hold	140	–	–	﹤0.01%	1174
2017 Q4	$42K	Buy	+140	New	+$39K	﹤0.01%	1080
2016 Q4	–	Sell	-34	Closed	-$11K	–	2088
2016 Q3	$11K	Hold	34	–	–	﹤0.01%	1345
2016 Q2	$14K	Hold	34	–	–	﹤0.01%	1238
2016 Q1	$11K	Buy	+34	New	+$11.6K	﹤0.01%	1280

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geneos Wealth Management's TXMD Position: Q2 2021 in Review

Geneos Wealth Management sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 23 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in TXMD in Q1 2016 and held it in 9 quarters. The position peaked at $45K in Q3 2018. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Geneos Wealth Management reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Geneos Wealth Management sold 23 TherapeuticsMD shares in Q2 2021, an estimated $1K.
Geneos Wealth Management first reported a position in TherapeuticsMD in Q1 2016 and held it in 9 quarters.
Geneos Wealth Management's TherapeuticsMD position peaked at $45K in Q3 2018.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.